

## Bluechiip completes placement

Bluechiip Limited (ASX: BCT), a leader in the development of advanced sample management solutions for harsh environments, today announced it has successfully raised \$367,600 (before costs). The \$367,000 was raised via a placement to institutional, sophisticated and professional investors (**Placement**) for 83.5 million new ordinary fully paid shares at an issue price of \$0.0044 per ordinary share (**New Shares**).

Mr Ohanessian supported the placement by subscribing for a total of A\$10,000 worth of New Shares. As Mr Ohanessian is a related party, his subscription is subject to shareholder approval at a General Meeting. The raising of \$367,600 is inclusive of the related party subscription.

The Company intends to use the proceeds for working capital purposes while undertaking a strategic review. Further details will be announced shortly.

The Company expects to resume normal trading on the ASX today, 12 June 2024, with the New Shares expected to be issued on Monday, 17 June 2024. The New Shares issued under the Placement will rank equally with existing shares on issue. The New Shares will be issued using the Company's existing capacity under ASX Listing Rule 7.1 and ASX Listing Rule 7.1A.

END

Authorised for release by the Bluechiip Limited Board

For more information, please contact:

### Corporate enquiries

Andrew McLellan  
Managing Director / CEO  
Ph: +61 457 823 470  
[andrew.mclellan@bluechiip.com](mailto:andrew.mclellan@bluechiip.com)

### Media

Richard Allen  
Oxygen Financial PR  
Ph: +61 403 493 049  
[richard@oxygenpr.com.au](mailto:richard@oxygenpr.com.au)

### About Bluechiip Limited

Bluechiip understands that every biological sample – stem cells, blood, eggs, sperm and other biospecimens – is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip’s Advanced Sample Management Solution is the only one that provides sample temperature with ID in cryogenic environments, driving productivity and improving quality. Bluechiip’s solution delivers confidence in every sample.

Bluechiip’s unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product is easily identified and critical information, such as sample temperature, detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip<sup>®</sup> Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip listed on the ASX in June 2011. Since then, it has significantly developed its technology. Today Bluechiip’s technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

Further information is available at [www.bluechiip.com](http://www.bluechiip.com)